Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on September 9, 2008
JNCI Journal of the National Cancer Institute 2008 100(18):1332-1333; doi:10.1093/jnci/djn270
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/18/1332    most recent
djn270v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Punglia, R. S.
Right arrow Articles by Weeks, J. C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Punglia, R. S.
Right arrow Articles by Weeks, J. C.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

CORRESPONDENCE

Response: Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis

Rinaa S. Punglia, Harold J. Burstein, Eric P. Winer, Jane C. Weeks

Affiliations of authors: Departments of Radiation Oncology (RSP) and Medical Oncology (HJB, EPW, JCW), Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Correspondence to: Rinaa S. Punglia, MD, MPH, Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, 44 Binney Street, Boston, MA 02115 (e-mail: rpunglia@partners.org).

The first 10% of the full text of this article appears below.

We thank Gurwitz and Newman for their interest in our findings. The authors make important points about the variation in CYP2D6 genotype distribution across ethnic populations. That very heterogeneity, as well as uncertainty about the effect of CYP2D6 genotype on outcomes of sequential treatment with tamoxifen . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis
David Gurwitz and William Newman
J Natl Cancer Inst 2008 100: 1331. [Extract] [Full Text] [PDF]

Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis
Rowan T. Chlebowski and Nananda Col
J Natl Cancer Inst 2008 100: 1331-1332. [Extract] [Full Text] [PDF]